3-FA Stats & Data

3-FA (PAL-353) is a monoamine releasing agent with high selectivity for dopamine and norepinephrine over serotonin in in vitro assays and in vivo primate studies, which correlates with reinforcing potential. Human pharmacokinetics are not established; user timelines suggest a 4–8 h primary effect window with residual stimulation and insomnia into the next day. Marked batch-to-batch potency variability has been reported; always allergy test (1–2 mg), use a milligram scale, and titrate slowly. Redosing can escalate cardiovascular strain and insomnia; set a hard cap and avoid extended binges (>24 h) due to psychosis/seizure risk. Stimulant risks include hypertension, tachycardia, vasoconstriction (cold extremities), hyperthermia, and dehydration; actively manage temperature and electrolytes, especially during dancing/exertion. Avoid combinations that raise serotonin (e.g., DXM, tramadol, MDMA) or lower seizure threshold (e.g., bupropion); MAOIs are a hard contraindication. Use drug checking: vendors sometimes mislabel ring-substituted amphetamines/cathinones; multi-reagent testing and, where available, spectrometric checking reduce adulterant risks. Nasal use increases local tissue irritation and infection risk; use clean equipment and isotonic saline rinses post-session. People with cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, or a history of psychosis should avoid use; anyone on prescription psych meds should consider interaction risks and spacing. Space sessions by at least 1–2 weeks to allow tolerance and sleep patterns to normalize; prioritize nutrition (carbohydrates, protein) and rehydration after use. Sexual compulsion and prolonged arousal are commonly reported; plan consent and protection ahead and beware of priapism risks.